Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.
|Articles|September 22, 2020
TFOS 2020 conference review
Author(s)Scott Schachter, OD
Advertisement
Scott Schachter, OD, reviews the The Tear Film and Ocular Surface Society's (TFOS) 2020 virtual meeting, which hosted global speakers presenting research on challenges and unmet needs of managing, diagnosing and treating ocular surface disease in their regions.
Advertisement
Related to this article
Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.
Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.
Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."
The company reported that Acuvue Oasys Max 1-Day and Oasys 1-Day outperformed the other 5 daily disposable lenses evaluated in a recent study, among other Johnson & Johnson data highlights at AAOpt 2026.
Three residents were honored for their leadership, education and research, and patient care contributions in ophthalmology, optometry, and retina.
American Academy of Optometry President Jeffrey Walline, OD, PhD, recommends attendees take advantage of the diverse array of educational and networking opportunities the conference offers.
Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: The underutilization of latanoprostene bunod 0.024% in glaucoma care
2
AAOpt 2026: The human cost of dry eye
3
AAOpt 2026: Insights into perimenopause and presbyopia
4
Johnson & Johnson Acuvue Oasys lenses demonstrate favorable moisture retention
5